MX2022013021A - Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. - Google Patents

Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.

Info

Publication number
MX2022013021A
MX2022013021A MX2022013021A MX2022013021A MX2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A
Authority
MX
Mexico
Prior art keywords
lung
leriglitazone
interstitial
treating
inflammation
Prior art date
Application number
MX2022013021A
Other languages
English (en)
Spanish (es)
Inventor
Sonia Maria Poli
Lalanza Maria Pilar Pizcueta
Marc Martinell Pedemonte
Anna Vilalta Saura
Estefania Traver López
Nuria Izquierdo Useros
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of MX2022013021A publication Critical patent/MX2022013021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022013021A 2020-04-30 2021-04-30 Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. MX2022013021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
MX2022013021A true MX2022013021A (es) 2023-01-16

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013021A MX2022013021A (es) 2020-04-30 2021-04-30 Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.

Country Status (11)

Country Link
US (1) US20230172921A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142720A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525981A (cg-RX-API-DMAC7.html)
KR (1) KR20230035522A (cg-RX-API-DMAC7.html)
CN (1) CN116390725A (cg-RX-API-DMAC7.html)
AU (1) AU2021265345A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180351A1 (cg-RX-API-DMAC7.html)
IL (1) IL297771A (cg-RX-API-DMAC7.html)
MX (1) MX2022013021A (cg-RX-API-DMAC7.html)
WO (1) WO2021220250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
JP2026500743A (ja) * 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US20120190637A1 (en) * 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX379710B (es) * 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
MX2020013182A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
EP4142720A1 (en) 2023-03-08
CN116390725A (zh) 2023-07-04
US20230172921A1 (en) 2023-06-08
IL297771A (en) 2022-12-01
CA3180351A1 (en) 2021-11-04
BR112022021951A2 (pt) 2022-12-13
AU2021265345A1 (en) 2022-12-08
JP2023525981A (ja) 2023-06-20
KR20230035522A (ko) 2023-03-14
WO2021220250A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
BR112022021951A2 (pt) Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial
LT3801515T (lt) 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dionas ir jo druskos, skirti mitochondrinių ligų gydymui
RU2011133833A (ru) Способы лечения синдрома сосудистой утечки
IL279186A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts
US20080194575A1 (en) Treatment for non-alcoholic-steatohepatitis
PH12019501318A1 (en) Novel phenyl derivatives
JP2014528450A5 (cg-RX-API-DMAC7.html)
CY1124116T1 (el) 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος
CY1125531T1 (el) Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της
SE0301232D0 (sv) Novel use
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2004517054A5 (cg-RX-API-DMAC7.html)
NZ610230A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
AR047541A1 (es) Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
EA200900913A1 (ru) Производное триазола в качестве ингибитора hsp90
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
AU2001292046A1 (en) Use of a ppar delta activator for treating inflammatory conditions
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
EA200701681A1 (ru) Пероральная лекарственная форма, содержащая росиглитазон
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
SE0402591D0 (sv) Novel use
AR023566A1 (es) Un procedimiento para el dihidrato del hidrocloruro derivado de la tiazolidina-2,4-diona
US20080207711A1 (en) Method for treating an ID2-related disorder